Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

WSE/CLN stock hub

WSE/CLN has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

WSE/CLNis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.1B

Warsaw Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

WSE/CLN

In the news

Latest news · WSE/CLN

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-27

P25 n/aP50 n/aP75 n/a

ROIC-29.9

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All WSE/CLN market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

193

Groups with data

Currency

PLN

Showing 193 of 193 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Poland
Country code	PL
Employees	566
Employees Change	4%
Employees Change Percent	0.71
Enterprise value	PLN 1.1B
Exchange	Warsaw Stock Exchange
Financial currency	PLN
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	PLCLNPH00015
Last refreshed	2026-05-10
Market cap	PLN 1.1B
Price	PLN 21.3
Price currency	PLN
Rev Per Employee	398,584.81x
Sector	Healthcare
Sic	2834
Symbol	wse/CLN
Website	https://www.celonpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-10.67%
EV Earnings	-9.32x
EV/FCF	-27.66x
EV/Sales	5.05x
FCF yield	-3.59%
P/B ratio	2.95x
P/S ratio	5.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-49.63%
EBITDA Margin	-38.14%
Gross margin	68.32%
Gross Profit	PLN 154.1M
Gross Profit Growth	5.44%
Gross Profit Growth Q	63.25%
Gross Profit Growth3 Y	7.59%
Gross Profit Growth5 Y	9.16%
Net Income	PLN -122.4M
Net Income Growth Q	-93.59%
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Pretax Margin	-56.05%
Profit Margin	-54.25%
Profit Per Employee	PLN -216,240
ROA	-12.84
Roa5y	-2.78
ROCE	-26.86
ROE	-27.03
Roe5y	-4.85
ROIC	-29.93
Roic5y	-7.56

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-11.63%
Cagr3y	14.67%
Cagr5y	-13.91%
Div CAGR3	-3.85%
Div CAGR5	2.71%
EPS Growth Q	-93.4
EPS Growth Quarters	1
EPS Growth Years	0
OCF Growth10 Y	-28.13%
OCF Growth5 Y	-58.09%
Revenue Growth	7.29x
Revenue Growth Q	39.34x
Revenue Growth Quarters	4x
Revenue Growth Years	1x
Revenue Growth3 Y	5.64x
Revenue Growth5 Y	9.68x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	PLN 0.41
Assets	PLN 471.3M
Cash	PLN 21M
Current Assets	PLN 103.2M
Current Liabilities	PLN 54.4M
Debt	PLN 14.2M
Debt Equity	PLN 0.04
Debt FCF	PLN -0.34
Equity	PLN 389.2M
Interest Coverage	-58.14
Liabilities	PLN 82.1M
Long Term Assets	PLN 368.2M
Long Term Liabilities	PLN 27.8M
Net Cash	PLN 6.8M
Net Cash By Market Cap	PLN 0.6
Net Cash Growth	-92.31%
Net Debt Equity	PLN -0.02
Tangible Book Value	PLN 386.5M
Tangible Book Value Per Share	PLN 7.18
WACC	8.22

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.9
Inventory Turnover	2.82
Net Working Capital	PLN 35.5M
Quick ratio	1.38
Working Capital	PLN 48.8M
Working Capital Turnover	PLN 2.66

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	1.95%
Dividend per share	PLN 0
Last Dividend	PLN 0.08

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-11.62%
200-day SMA	21.74
3Y total return	50.79%
50-day SMA	21.02
50-day SMA vs 200-day SMA	50under200
5Y total return	-52.7%
All Time High	57
All Time High Change	-62.63%
All Time High Date	2021-01-11
All Time Low	12
All Time Low Change	77.5%
All Time Low Date	2022-10-13
ATR	0.49
Beta	0.72
Beta1y	0.72
Beta2y	0.69
Ch YTD	4.67
High	21.55
High52	25.3
High52 Date	2025-07-03
High52ch	-15.81%
Low	21.1
Low52	18.5
Low52 Date	2025-12-23
Low52ch	15.14%
Ma50ch	1.32%
Price vs 200-day SMA	-2%
RSI	54.02
RSI Monthly	48.16
RSI Weekly	48.96
Sharpe ratio	-0.55x
Sortino ratio	-0.58
Total Return	1.95%
Tr YTD	4.67
Tr1m	4.93%
Tr1w	0.24%
Tr3m	-8.19%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	PLN -112M
Operating Income Growth Q	-85.77
Operating margin	-49.63

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	23,828,969%
Net Borrowing	-10,328,000
Shares Institutions	10.36%
Shares Out	53,856,500
Shares Qo Q	-2.57%
Shares Yo Y	-1.95%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	PLN -39M
Average Volume	8,650.85x
Bv Per Share	7.23
CAPEX	PLN -41.7M
Ch1m	4.93
Ch1w	0.24
Ch1y	-11.62
Ch3m	-8.19
Ch3y	49.16
Ch5y	-54.14
Ch6m	-1.84
Change	-1.39%
Change From Open	-0.93
Close	21.6
Days Gap	-0.46
Depreciation Amortization	25,926,000
Dollar Volume	314,750.1
Earnings Date	2026-04-22
EBIT	PLN -112M
EBITDA	PLN -86M
EPS	PLN -2.36
F Score	3
FCF	PLN -41.2M
FCF EV Yield	-3.62x
FCF Per Share	PLN -0.77
Financing CF	-16,094,000
Fiscal Year End	December
Founded	2,002
Income Tax	PLN -4.1M
Investing CF	11,287,000
Is Primary Listing	1
Last Earnings Date	2026-04-22
Last Report Date	2025-09-30
Ma150	21.39
Ma150ch	-0.42%
Ma20	21.18
Ma20ch	0.59%
Net CF	-4,335,000
Next Earnings Date	2026-05-20
Open	21.5
P OCF Ratio	2,425.3
Position In Range	44.44
Ppne	294,656,000
Price Date	2026-05-08
Ptbv Ratio	2.97
Relative Volume	1.82x
Revenue	225,599,000x
SBC By Revenue	-1.01x
Share Based Comp	-2,275,000
Tax By Revenue	-1.8x
Tr6m	-1.84%
Volume	14,777
Z Score	9.12

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does WSE/CLN pay a dividend?

Capital-return profile for this ticker.

Performance

WSE/CLN stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns WSE/CLN?

Insider, institutional, and short-interest positioning.

Institutional ownership

+10.4%

Share of float held by funds and institutions

Insider ownership

n/a

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-2.0%

Negative means the company is buying back shares.

Technical

WSE/CLN momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

54.0

Neutral momentum band

Price vs 200-day MA

-2.0%

50/200-day relationship not available

Beta (5Y)

0.72

Less volatile than the market

Sharpe ratio

-0.55

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About WSE/CLN

Hub-level FAQ points readers to the deeper analysis pages.

What is the current wse/CLN stock rating?

wse/CLN is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full wse/CLN analysis?

The full report lives at /stocks/wse/CLN/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for wse/CLN?

The latest report frames wse/CLN around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the wse/CLN page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.